Nature of Business and Basis of Presentation (Details) - USD ($)
$ / shares in Units, $ in Thousands |
|
|
|
1 Months Ended |
12 Months Ended |
Dec. 10, 2021 |
Nov. 19, 2020 |
Oct. 27, 2020 |
Jan. 31, 2022 |
Jul. 31, 2020 |
Dec. 31, 2021 |
Dec. 31, 2020 |
| Organization Consolidation And Presentation Of Financial Statements |
|
|
|
|
|
|
|
| Upfront payment received |
|
|
|
|
$ 15,000
|
$ 15,000
|
|
| Net loss |
|
|
|
|
|
(101,320)
|
$ (68,800)
|
| Accumulated deficit |
|
|
|
|
|
$ 264,256
|
$ 162,936
|
| Eli Lilly | Subsequent Event |
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements |
|
|
|
|
|
|
|
| Upfront payment received |
|
|
|
$ 300,000
|
|
|
|
| IPO |
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements |
|
|
|
|
|
|
|
| Stock issued during the period shares new issues shares (in shares) |
|
|
7,500,000
|
|
|
|
|
| Sale of stock issue price per share (in dollars per share) |
|
|
$ 16.00
|
|
|
|
|
| Sale of stock consideration received on the transaction |
|
|
$ 107,900
|
|
|
|
|
| IPO | Common Stock |
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements |
|
|
|
|
|
|
|
| Stock issued during the period shares new issues shares (in shares) |
|
|
7,500,000
|
|
|
|
|
| Sale of stock issue price per share (in dollars per share) |
|
|
$ 16.00
|
|
|
|
|
| Sale of stock consideration received on the transaction |
|
|
$ 107,900
|
|
|
|
|
| Over-Allotment Option |
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements |
|
|
|
|
|
|
|
| Stock issued during the period shares new issues shares (in shares) |
|
951,837
|
|
|
|
|
|
| Sale of stock issue price per share (in dollars per share) |
|
$ 16.00
|
|
|
|
|
|
| Sale of stock consideration received on the transaction |
|
$ 14,200
|
|
|
|
|
|
| Over-Allotment Option | Common Stock |
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements |
|
|
|
|
|
|
|
| Stock issued during the period shares new issues shares (in shares) |
|
951,837
|
|
|
|
|
|
| Sale of stock issue price per share (in dollars per share) |
|
$ 16.00
|
|
|
|
|
|
| Sale of stock consideration received on the transaction |
|
$ 14,200
|
|
|
|
|
|
| Share Purchase Agreement | Eli Lilly |
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements |
|
|
|
|
|
|
|
| Sale of stock issue price per share (in dollars per share) |
$ 20.00
|
|
|
|
|
|
|
| Sale of stock consideration received on the transaction |
$ 80,000
|
|
|
|
|
|
|
| Sale of stock, number of shares issued in transaction (in shares) |
4,000,000
|
|
|
|
|
|
|
| Share Purchase Agreement | Eli Lilly | Common Stock |
|
|
|
|
|
|
|
| Organization Consolidation And Presentation Of Financial Statements |
|
|
|
|
|
|
|
| Sale of stock consideration received on the transaction |
$ 42,200
|
|
|
|
|
|
|